CRISPR-Tweaked donor cells take on Hard-to-Treat blood cancers
NCT ID NCT04035434
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new treatment called CTX110 for people with B-cell blood cancers that came back or didn't respond to standard therapy. CTX110 uses donor immune cells that are edited with CRISPR technology to target and attack cancer cells. The trial enrolled 93 adults and aimed to check safety and how well the treatment works, but it was stopped early, so the full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CTX110 (CRISPR-edited donor immune cells targeting CD19)
What this could lead to
If successful, this could point toward a readily available 'off-the-shelf' cell therapy for certain blood cancers, reducing the need for patient-specific treatments.
What could go wrong
The trial was terminated early, so data is limited. As an early-phase study, safety and effectiveness are not yet proven, and there are risks like graft-versus-host disease and severe side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
CHU de Lille
Lille, 59000, France
-
Cedars Sinai
Los Angeles, California, 90048, United States
-
Clinica Universidad de Navarra
Pamplona, Navarre, 31008, Spain
-
Duke University
Durham, North Carolina, 27710, United States
-
Emory University Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center
Dallas, Texas, 75390, United States
-
Hospital Clínic de Barcelona
Barcelona, 08036, Spain
-
Hospital Universitario de Salamanca
Salamanca, 37007, Spain
-
Hôpital Saint Antoine
Paris, 75012, France
-
Institut Paoli-Calmettes
Marseille, 13009, France
-
Markey Cancer Center, University of Kentucky
Lexington, Kentucky, 40536, United States
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, 3000, Australia
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
-
Roswell Park Cancer Insitute
Buffalo, New York, 14203, United States
-
Royal Prince Alfred Hospital
Sydney, New South Wales, 2050, Australia
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Sir Charles Gairdner Hospital
Nedlands, Western Australia, 6009, Australia
-
Swedish Cancer Institute
Seattle, Washington, 98104, United States
-
Texas Transplant Institute
San Antonio, Texas, 78229, United States
-
UCSF Medical Center
San Francisco, California, 94143, United States
-
University Hospital Würzburg
Würzburg, 97080, Germany
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Hamburg
Hamburg, 20148, Germany
-
University of Kansas
Westwood, Kansas, 66205, United States
-
University of Maryland
Baltimore, Maryland, 21201, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
-
Virginia Commonwealth University Massey Cancer Center
Richmond, Virginia, 23298, United States
-
Washington University
St Louis, Missouri, 63130, United States
-
Weill Cornell Medical College / New York Presbyterian Hospital
New York, New York, 10021, United States